Scholars@Duke
Jeffrey Rae Gingrich

Jeffrey Rae Gingrich

Professor of Urology
Urology
jeffrey.gingrich@duke.edu
DUMC 3707, Durham, NC 27710
DUMC 3707, Durham, NC 27710
Office hours

Selected Publications

Genomic classifiers and prognosis of localized prostate cancer: a systematic review.

Journal Article Prostate Cancer Prostatic Dis · March 2025 BACKGROUND: Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolar ... Full text Link to item Cite

Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer : A Systematic Review.

Journal Article Ann Intern Med · February 2025 BACKGROUND: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations. PURPOSE: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris ... Full text Link to item Cite

Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access Setting.

Journal Article Fed Pract · August 2022 BACKGROUND: Moderately hypofractionated radiotherapy (MHRT) is an accepted treatment for localized prostate cancer; however, limited MHRT data address high-risk prostate cancer (HRPC) and/or African American patients. We report clinical outcomes and toxici ... Full text Link to item Cite

The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.

Journal Article Cancer · November 1, 2021 BACKGROUND: The objective of this study was to describe bladder cancer outcomes as a function of race among patients with high-risk non-muscle-invasive bladder cancer (NMIBC) in an equal-access setting. METHODS: A total of 412 patients with high-risk NMIBC ... Full text Link to item Cite

Head to head randomized trial of two decision aids for prostate cancer.

Journal Article BMC Med Inform Decis Mak · May 12, 2021 BACKGROUND: While many studies have tested the impact of a decision aid (DA) compared to not receiving any DA, far fewer have tested how different types of DAs affect key outcomes such as treatment choice, patient-provider communication, or decision proces ... Full text Link to item Cite

Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer.

Journal Article Urology · May 2021 OBJECTIVE: To investigate the association of female sex with the selected treatment for patients with nonmetastatic muscle-invasive bladder cancer. Sex is a known independent predictor of death from bladder cancer. A potential explanation for this survival ... Full text Link to item Cite

Increasing use of positron emission tomography among medicare beneficiaries undergoing radical cystectomy.

Journal Article Eur J Cancer Care (Engl) · July 2020 OBJECTIVE: To examine factors associated with PET scan use in the pre-operative evaluation of patients diagnosed with bladder cancer. METHODS: Using SEER-Medicare data, we identified bladder cancer patients who underwent radical cystectomy from 2006 to 201 ... Full text Link to item Cite

Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Journal Article Clin Genitourin Cancer · June 2020 BACKGROUND: We use observational methods to compare impact of perioperative chemotherapy timing (ie, neoadjuvant and adjuvant) on overall survival (OS) in muscle-invasive bladder cancer because there is no head-to-head randomized trial, and patient factors ... Full text Link to item Cite

EDITORIAL COMMENT.

Journal Article Urology · February 2020 Full text Link to item Cite

The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction.

Journal Article J Alzheimers Dis · 2020 BACKGROUND: Perioperative neurocognitive disorders (PND) are common complications in older adults associated with increased 1-year mortality and long-term cognitive decline. One risk factor for worsened long-term postoperative cognitive trajectory is the A ... Full text Open Access Link to item Cite

Implications of Cystectomy Travel Distance for Hospital Readmission and Survival.

Journal Article Clin Genitourin Cancer · December 2019 BACKGROUND: Regionalization of complex surgical care results in increasing need for patients to travel for complex oncologic procedures such as cystectomy in bladder cancer. We examined the association between travel distance to a cystectomy center, readmi ... Full text Link to item Cite

E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer.

Journal Article Prostate · August 2019 BACKGROUND: We previously reported the presence of prostate-specific antigen (PSA) in the stromal compartment of benign prostatic hyperplasia (BPH). Since PSA is expressed exclusively by prostatic luminal epithelial cells, PSA in the BPH stroma suggests in ... Full text Link to item Cite

Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.

Journal Article Urol Oncol · July 2019 INTRODUCTION: Contemporary guidelines recommend cystectomy with neoadjuvant or adjuvant cisplatin-based chemotherapy given with curative intent for patients with resectable muscle-invasive bladder cancer (MIBC). However, rates and appropriateness of periop ... Full text Link to item Cite

Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.

Journal Article J Clin Oncol · May 20, 2019 PURPOSE: This randomized clinical trial compared a personally tailored, automated telephone symptom management intervention to improve self-management among long-term survivors of prostate cancer with usual care enhanced with a nontailored newsletter about ... Full text Link to item Cite

Small cell bladder cancer: should we consider prophylactic cranial irradiation?

Journal Article Int Braz J Urol · 2019 PURPOSE: To describe the clinical characteristics, treatment patterns, and outcomes in patients with small cell bladder cancer at our institution, including those who received prophylactic cranial irradiation (PCI) for the prevention of intracranial recurr ... Full text Open Access Link to item Cite

The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients.

Journal Article Can J Urol · April 2018 INTRODUCTION: Multimodal analgesia is an effective way to control pain and limit opioid use after surgery. The quadratus lumborum block and paravertebral block are two regional anesthesia techniques that leverage multimodal analgesia to improve postoperati ... Link to item Cite

Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.

Journal Article Prostate · January 2018 PURPOSE: Benign prostatic hyperplasia (BPH) is strongly associated with obesity and prostatic tissue inflammation, but the molecular underpinning of this relationship is not known. Here, we examined the association between urine levels of chemokines/adipok ... Full text Link to item Cite

Aggressive surgical management of adenocarcinoma of the rete testis.

Journal Article Urol Case Rep · January 2018 Adenocarcinoma of the rete testis is a rare and aggressive malignancy arising from the epididymal epithelium. We present a case of a 66-year-old male who presented with left testis mass. Histopathological analysis of orchiectomy specimen was consistent wit ... Full text Link to item Cite

Preoperative immunonutrition prior to radical cystectomy: a pilot study.

Journal Article Can J Urol · August 2017 INTRODUCTION: To investigate the use of a high-arginine immunonutrient supplement prior to radical cystectomy for bladder cancer. MATERIALS AND METHODS: We recruited 40 patients to consume a total of four high-arginine immunonutrient shakes per day for 5 d ... Link to item Cite

Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial.

Journal Article Trials · April 18, 2017 BACKGROUND: Although prostate cancer is the most common cancer among veterans receiving care in the Veterans Health Administration (VA), more needs to be done to understand and improve survivorship care for this large population. This study, funded by VA H ... Full text Link to item Cite

Urine chemokines indicate pathogenic association of obesity with BPH/LUTS.

Journal Article Int Urol Nephrol · July 2015 OBJECTIVES: High prevalence of lower urinary tract symptoms (LUTS) consistent with benign prostate hyperplasia (BPH) is associated with obesity and prostatic inflammation. Here, we investigated whether chemokines associated with obesity and prostatic infla ... Full text Link to item Cite

5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.

Journal Article J Urol · April 2015 PURPOSE: Intermittent androgen deprivation therapy in patients with prostate specific antigen progression after localized prostate cancer treatment is an alternative to standard continuous androgen deprivation therapy. Intermittent androgen deprivation the ... Full text Link to item Cite

Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats.

Journal Article Prostate · March 1, 2015 BACKGROUND: Prostatic inflammation is reportedly associated with the development of prostatic hyperplasia. We investigated the effects of prostatic inflammation on expression levels of androgen-responsive genes and growth factors in the rat prostate. METHO ... Full text Link to item Cite

Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.

Journal Article J Immunother Cancer · 2015 BACKGROUND: BCG is a prototypal cancer immunotherapeutic factor currently approved of bladder cancer. In attempt to further enhance the effectiveness of immunotherapy of bladder cancer and, potentially, other malignancies, we evaluated the impact of BCG on ... Full text Link to item Cite

Total Psoas Area Predicts Complications following Radical Cystectomy.

Journal Article Adv Urol · 2015 Purpose. To determine whether total psoas area (TPA), a simple estimate of muscle mass, is associated with complications after radical cystectomy. Materials and Methods. Patients who underwent radical cystectomy at our institution from 2011 to 2012 were re ... Full text Link to item Cite

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer.

Journal Article Adv Urol · 2015 Background. Thirty to forty percent of patients with high grade nonmuscle invasive bladder cancer (NMIBC) fail to respond to intravesical therapy with bacillus Calmette-Guerin (BCG). Interferon-α2B plus BCG has been shown to be effective in a subset of pat ... Full text Link to item Cite

Inflammasomes are important mediators of prostatic inflammation associated with BPH.

Journal Article J Inflamm (Lond) · 2015 BACKGROUND: There is mounting evidence to support the role of inflammation in benign prostate hyperplasia (BPH), and a recent study reported expression of inflammasome derived cytokine IL-18 in prostate biopsy of BPH patients. Here we examined the expressi ... Full text Link to item Cite

Comprehensive molecular characterization of urothelial bladder carcinoma.

Journal Article Nature · March 20, 2014 Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we r ... Full text Link to item Cite

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.

Journal Article Clin Cancer Res · December 15, 2013 PURPOSE: Tasquinimod (Active Biotech) is an oral immunomodulatory, anti-angiogenic, and anti-metastatic agent that delayed metastatic disease progression in a randomized placebo-controlled phase II trial in men with metastatic castration-resistant prostate ... Full text Link to item Cite

Comprehensive handbook for developing a bladder cancer cystectomy database.

Journal Article Urol Oncol · August 2013 OBJECTIVE: In an effort to standardize data collection for research regarding bladder cancer, the Bladder Cancer Working Group sought to provide a handbook that can be used as a guide for prospective or retrospective data collection. METHODS: Expert opinio ... Full text Link to item Cite

Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression.

Journal Article Biochem Biophys Res Commun · June 14, 2013 Cell adhesion molecules (CADMs) comprise a protein family whose functions include maintenance of cell polarity and tumor suppression. In this report, we show that the CADM2 gene is repressed in human clear renal cell carcinoma by DNA promoter hypermethylat ... Full text Link to item Cite

CLT1 targets bladder cancer through integrin α5β1 and CLIC3.

Journal Article Mol Cancer Res · February 2013 High-grade non-muscle-invasive bladder cancer is commonly treated with Bacillus Calmette-Guérin, an immunotherapeutic that depends on fibronectin and tumor cell integrin α5β1 for internalization into bladder cancer cells. We previously showed that the anti ... Full text Link to item Cite

Radical prostatectomy versus observation for localized prostate cancer.

Journal Article N Engl J Med · July 19, 2012 BACKGROUND: The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known. METHODS: From November 1994 through January 2002, we randomly assigned 731 men wit ... Full text Link to item Cite

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Journal Article J Clin Oncol · October 20, 2011 PURPOSE: The activity of the novel antitumor agent tasquinimod (TASQ) with S100A9 as a molecular target was investigated in men with metastatic castration-resistant prostate cancer (CRPC) and minimal symptoms. PATIENTS AND METHODS: We conducted a randomize ... Full text Link to item Cite

Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens via proteomic analysis.

Journal Article Electrophoresis · August 2011 Early detection of prostate cancer and determination of its aggressiveness are critical factors that influence treatment outcomes. To aid in the clinical decision making, novel biomarkers are being sought. Direct, global-scale examination of primary human ... Full text Link to item Cite

Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.

Journal Article Journal of Clinical Oncology · March 1, 2011 126 Background: Tasquinimod (TASQ) is an oral quinoline-3-carboxamide derivative that binds to S100A9 and displays anti-angiogenic and anti-tumor activity in prostate cancer (PC) models. In a randomized blinded phase II study, 20 ... Full text Cite

Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups.

Journal Article J Clin Oncol · March 2011 126 Background: Tasquinimod (TASQ) is an oral quinoline-3-carboxamide derivative that binds to S100A9 and displays anti-angiogenic and anti-tumor activity in prostate cancer (PC) models. In a randomized blinded phase II study, 206 (136 TASQ, 70 placebo [P] ... Link to item Cite

Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?

Journal Article Oncology (Williston Park) · November 15, 2010 Link to item Cite

Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.

Journal Article Clin Cancer Res · November 15, 2010 PURPOSE: Cell adhesion molecules (CADM) comprise a newly identified protein family whose functions include cell polarity maintenance and tumor suppression. CADM-1, CADM-3, and CADM-4 have been shown to act as tumor suppressor genes in multiple cancers incl ... Full text Link to item Cite

Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.

Journal Article J Urol · April 2010 PURPOSE: Vesicular stomatitis virus has been investigated as an oncolytic agent for cancer therapy because it preferentially replicates in tumor but not in normal cells due to the lack of a robust interferon antiviral system in transformed cells. However, ... Full text Link to item Cite

Investigational therapies for non-muscle invasive bladder cancer.

Journal Article Expert Opin Investig Drugs · March 2010 IMPORTANCE OF THE FIELD: Bacillus Calmette-Guérin (BCG) is currently the most effective adjuvant intravesical agent at preventing disease recurrence and the only therapy shown to inhibit disease progression in non-muscle invasive bladder cancer (NMIBC). Ho ... Full text Link to item Cite

Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.

Journal Article Minerva Urol Nefrol · June 2009 Transitional cell carcinoma (TCC) is the second most common urologic malignancy, and 70% of patients present with superficial, or non-muscle invasive disease (NMIBC). Bacillus Calmette-Guerin (BCG), currently the most effective intravesical agent at preven ... Link to item Cite

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.

Journal Article Contemp Clin Trials · January 2009 BACKGROUND: Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. Ninety percent of men with prostate cancer are over aged 60 years, diagnosed by early detection with the prostate specific antigen ( ... Full text Link to item Cite

U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.

Journal Article Oncogene · March 6, 2008 Upregulated gene 19 (U19)/ELL-associated factor 2 (Eaf2) is a potential human tumor suppressor that exhibits frequent allelic loss and downregulation in high-grade prostate cancer. U19/Eaf2, along with its homolog Eaf1, has been reported to regulate transc ... Full text Link to item Cite

Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.

Journal Article Mol Cancer Res · December 2003 Loss of heterozygosity or mutation at the p53 tumor suppressor gene locus is frequently associated with advanced human prostate cancer. Hence, replacement p53 gene therapy may prove to be efficacious for this disease. While many mutations result in p53 mol ... Link to item Cite

Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome.

Journal Article Biol Blood Marrow Transplant · November 2003 Hemorrhagic cystitis (HC) is a well-documented adverse event experienced by patients undergoing hematopoietic stem cell transplantation. When severe, HC causes significant morbidity, leads to renal complications, prolongs hospitalization, increases health- ... Full text Link to item Cite

Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice.

Journal Article Differentiation · December 2002 The minimal rat probasin (PB) promoter was used to target expression of human fibroblast growth factor-7 (FGF-7)/keratinocyte growth factor (KGF) directly to prostatic epithelium of transgenic mice, converting FGF-7 from a paracrine to an autocrine factor. ... Full text Link to item Cite

Analysis of the proteome in the human prostate

Conference Proceedings 50th Asms Conference on Mass Spectrometry and Allied Topics · December 1, 2002 Applications of proteomics to the study of the human prostate were discussed. Number of prominent prostate proteins were identified and pilot data were obtained on the alterations in protein expression related to prostate aging and benign prostatic hyperpl ... Cite

Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice.

Journal Article Urology · November 2002 OBJECTIVES: To investigate the effects of flaxseed supplementation on prostatic neoplasia in the transgenic adenocarcinoma mouse prostate (TRAMP) model. METHODS: A total of 135 male TRAMP mice 5 to 6 weeks old were randomized to a control group (AIN-76A di ... Full text Link to item Cite

Prostate cancer gene therapy.

Journal Article Surg Oncol Clin N Am · July 2002 Numerous gene therapy trials in the United States and throughout the world using various strategies are in progress for the treatment of locally advanced and metastatic prostate cancer. Although vector technology advances at a rapid pace, progress in eluci ... Full text Link to item Cite

Transrectal gene therapy of the prostate in the canine model.

Journal Article Cancer Gene Ther · February 2002 Direct transrectal delivery of therapeutic genes utilizing adenoviral vectors for advanced prostate cancer may offer effective treatment at the molecular level. Large animal models to assess feasibility and the intraprostatic and systemic dissemination pat ... Full text Link to item Cite

Importance of delayed imaging for blunt renal trauma.

Journal Article World J Surg · December 2001 The advent of noninvasive computed tomography of the abdomen and pelvis for evaluation of blunt renal trauma has led to the practice of expectant management for hemodynamically stable patients. Although expectant management of higher grade injuries (Americ ... Full text Link to item Cite

Gene therapy for prostate cancer.

Journal Article Curr Oncol Rep · September 2001 Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spa ... Full text Link to item Cite

THE NATURAL PROGRESSION OF ADENOCARCINOMA OF THE EPIDIDYMIS

Journal Article The Journal of Urology · August 2001 Full text Cite

Gene therapy for prostate cancer.

Journal Article Curr Urol Rep · June 2001 Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spa ... Full text Link to item Cite

Impact of urethral injury management on the treatment and outcome of concurrent pelvic fractures.

Journal Article Urology · March 2001 OBJECTIVES: Multiple treatment options exist for concurrent posterior urethral trauma and pelvic fractures. Because of the increased risk of contamination, the surgical repair of fractures may be prohibited by suprapubic urologic catheters. To characterize ... Full text Link to item Cite

Bcl-2 accelerates multistep prostate carcinogenesis in vivo.

Journal Article Oncogene · November 2, 2000 The impact of bcl-2 proto-oncogene expression on the pathogenesis and progression of prostate cancer was examined in a transgenic mouse model. Probasin-bcl-2 transgenic mice were crossed with TRAMP (TRansgenic Adenocarcinoma Mouse Prostate) mice that expre ... Full text Link to item Cite

Gene therapy for prostate cancer: where are we now?

Journal Article J Urol · October 2000 PURPOSE: The ability to recombine specifically and alter DNA sequences followed by techniques to transfer these sequences or even whole genes into normal and diseased cells has revolutionized medical research and ushered the clinicians of today into the ag ... Link to item Cite

GENE THERAPY FOR PROSTATE CANCER: WHERE ARE WE NOW?

Journal Article The Journal of Urology · October 2000 Full text Cite

The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo.

Journal Article Oncogene · May 11, 2000 Prostatic glandular epithelial cells undergo apoptosis in response to androgen-deprivation. The molecular determinants of androgen-responsiveness in these cells are incompletely understood. Recent evidence suggests that bcl-2 gene family members may be imp ... Full text Link to item Cite

Gene therapy in urologic oncology.

Journal Article World J Urol · April 2000 Full text Link to item Cite

Imaging findings of hemorrhagic cystitis in pediatric oncology patients.

Journal Article Pediatr Radiol · March 2000 In pediatric oncology patients, hemorrhagic cystitis may be a life-threatening complication of bone-marrow transplantation, chemotherapy, and/or radiation therapy. The inciting agent in urine can affect the entire urothelium from the renal collecting syste ... Full text Link to item Cite

Erratum: C-CAM adhesion in mouse model (Journal of Urology 162:3 (892))

Journal Article Journal of Urology · January 1, 2000 Cite

C-CAM adhesion in mouse model (vol 162, pg 892, 1999)

Journal Article JOURNAL OF UROLOGY · January 1, 2000 Link to item Cite

Pathologic progression of autochthonous prostate cancer in the TRAMP model.

Journal Article Prostate Cancer Prostatic Dis · March 1999 The ability to manipulate gene expression in specific cell types at specific times utilizing transgenic technology has allowed the development of novel mouse model systems that can mimic human disease. We have previously established the Transgenic Adenocar ... Full text Link to item Cite

A gene hunting we will go!

Journal Article Urol Res · 1998 Two general approaches toward the identification of new genes which may contribute to specific developmental, physiologic, or pathologic processes can be pursued: (1) a strategy of positional cloning or reverse genetics and linkage analysis in which affect ... Full text Link to item Cite

Androgen-independent prostate cancer progression in the TRAMP model.

Journal Article Cancer Res · November 1, 1997 We previously established the autochthonous transgenic adenocarcinoma mouse prostate (TRAMP) model to facilitate characterization of molecular mechanisms involved in the initiation and progression of prostate cancer. TRAMP mice display high grade prostatic ... Link to item Cite

Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.

Journal Article Cancer Res · August 15, 1997 To develop a syngeneic transplantable system to study immunotherapeutic approaches for the treatment of prostate cancer, three cell lines were established from a heterogeneous 32 week tumor of the transgenic adenocarcinoma mouse prostate (TRAMP) model. TRA ... Link to item Cite

Metastatic prostate cancer in a transgenic mouse.

Journal Article Cancer Res · September 15, 1996 We have previously reported the development of a transgenic mouse model for prostate cancer derived from PB-Tag transgenic line 8247, henceforth designated the TRAMP (transgenic adenocarcinoma mouse prostate) model. We now describe the temporal and spatial ... Link to item Cite

The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy?

Journal Article Surg Oncol Clin N Am · April 1995 Despite a negative metastatic evaluation, up to 100% of patients with high-grade tumors are found to harbor metastatic disease within the pelvic lymph nodes at the time of surgery. This article reviews the literature regarding efforts to refine noninvasive ... Link to item Cite

Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model.

Journal Article Cancer Res · January 15, 1994 An in vivo study of cisplatin (CDDP) and 5-fluorouracil (5FU) cytotoxicity was performed using a multidose matrix with a human bladder transitional cell carcinoma xenograft tumor line (DU4284) tested by subrenal capsule assay in 154 nude mice (NM-SRCA). St ... Link to item Cite

The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.

Journal Article J Urol · November 1991 Using an in vivo assay of tumor cytotoxicity (the subrenal capsule assay in nude mice), two therapeutic strategies for the treatment of advanced human transitional cell carcinoma have been evaluated: 1) the use of 5-fluorouracil in combination with cisplat ... Full text Link to item Cite

Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1).

Journal Article J Urol · September 1991 A new human prostate adenocarcinoma cell line (DuPro-1) has been established from the athymic nude mouse supported xenograft DU5683. This was accomplished by embedding dispersed xenograft cells in 0.1 by 5.0 cm. spaghetti-like strands of Basement Membrane ... Full text Link to item Cite